Cobra Biologics is to manufacture Scancell Holdings COVID-19 vaccine. The agreement covers Good Manufacturing Practice (GMP) production of plasmid DNA needed to generate the DNA vaccine, against SARS-CoV-2, for use in a Phase I clinical trial in 2021 (COVIDITY). The project is funded by an Innovate UK grant awarded to the consortium between Scancell, the […]
